NSIV Member Spotlight - Cellanyx

For years oncology practice has continued to both over- and under-treat cancer patients. Though not always mistreated, aggressive and indolent cancers are difficult for clinicians to distinguish between. Therefore, the treatment decision is often left to the preference of the patient. Cellanyx has developed a cutting-edge solution by combining two of the most exciting technologies in medical science: single cell analysis and machine learning/AI.

Traditionally, scientists analyze dead tumor cells from a biopsy. Alternatively, Cellanyx studies the behaviors of live tumor cells. This uncovers how aggressive or abnormal the tumor cells are because, as CEO Guy L. Fish explains, “live tumor cells don’t lie.” The tumor cells are cultured proprietary extracellular matrices that do not alter their behaviors or markers. Cellanyx’ technology tracks thousands of cells and hundreds of markers per cell at once, over multiple time periods, for one tumor sample. Millions of measurements of cell behaviors are then analyzed by machine learning algorithms. Cellanyx’ most recent work revolves around prostate cancer treatment decisions since the traditional risk assessment
test is only 65% accurate. Cellanyx' predictive metrics has an overall accuracy of 88% (specificity = 92%) which is significantly higher than any current prostate test.

This is great news for the 250,000 prostate cancer patients each year who are forced to make treatment decisions without adequate information.

... read more.

NSIV Welcomes New Board Member

**Chad Robinson**, Principal at **Kevin P. Martin & Associates**, has joined the Board of Directors. He is serving as Treasurer, assuming the role of retiring Treasurer Gordon W. Ulen, CPA. Our sincere thanks to Gordon for his many years of service to NSIV.

Chad's practice at KPM encompasses numerous clients in a variety of industries including private enterprise, technology, life sciences, entertainment, real estate and not-for-profit.

Formerly with Ernst & Young, Chad is a seasoned professional with more than 20 years of public accounting experience. Chad provides extensive accounting, tax and management consulting services, including mergers and acquisitions, private equity placement, tax structuring, business start up consulting, valuation and financial modeling.

KPM is a **Silver Sponsor** of NSIV and Chad holds office hours to work with members. In addition, Chad and several of his colleagues are currently guiding NSIV in transitioning to a paperless financial system.

Keeping up with NSIV

NSIV CEO **Chris Ilsley** is traveling internationally next month. Following a visit from a life sciences delegation in April, Chris and two current NSIV members and a graduate have been invited to the 2019 Regional Promotion Project in Kyoto, Japan. They will join others in a challenge to create the Healthcare Ecosystem in Kyoto. The project features three events - first the Healthcare Venture Conference showcasing 20+ New Innovations in Healthcare, followed by a Regional Business Conference, and then a third day visiting Kyoto University's **Innovation Hub Kyoto**.

Chris will be presenting as well as offering a poster that explains how **NSIV** works - our mission, vision and all that we offer member companies including our Soft Landing program, a suite of services designed to help international companies adapt and thrive in the US business environment.
Also presenting is **Gitte Pederen**, CEO of member company **Genomic Expression**. In addition, the CEO of **Cellanyx**, **Guy Fish**, will be on hand along with NSIV graduate **Thrive Bioscience** represented by CEO **Tom Farb**. It appears that four of the six U.S. attendees are part of the NSIV family!

Early this year we missed some news to share about NSIV graduate **Windgap Medical**. A press release from January announced a strategic investment by Molex Ventures, LLC, a subsidiary of Koch Industries. If you are not familiar with Windgap Medical, they have a drug delivery platform - a wet/dry autoinjector called the ANDIPen® with the first product planned to be one using epinephrine for the treatment of anaphylaxis. Read the full press release [here](#). They've also found success in getting patents approved, with three new patents issued last month, bringing the total to eight!

Today, while reading about the MLSC's **Massachusetts Next Generation Initiative**, we were very pleased to find NSIV member **Suzanne Mitchell**, CEO of **See Yourself Health**, named as one of five 2019 recipients. Here's the [announcement](#).

**See Yourself Health** is a digital health platform to reverse the course of diabetes through virtual reality technology. (Please see our March 2019 newsletter for more information)

The NextGen Initiative is a competitive program that supports "women entrepreneurs in early stage life sciences companies" according to the current
MLSC Newsletter. Congrats to Suzanne and all the winners!

**What's Happening Around the North Shore & Beyond**

When: June 27, 2019, 8:00 am - 7:00 pm
Where: Kendall Square Marriott, 50 Broadway, Cambridge, MA

**Happy Independence Day** to all as we get ready to celebrate! If you are looking for a nearby fireworks display, then here's a [list](#) by town to help get your holiday planning started!